TG Therapeutics Inc. (TGTX) poses a Brand-New Opportunity for Investors with beta value of 2.14


Witnessing the stock’s movement on the chart, on November 23, 2022, TG Therapeutics Inc. (NASDAQ: TGTX) set off with pace as it heaved 0.49% to $8.17. During the day, the stock rose to $8.31 and sunk to $8.075 before settling in for the price of $8.13 at the close. Taking a more long-term approach, TGTX posted a 52-week range of $3.48-$25.60.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


The Healthcare sector firm’s twelve-monthly sales growth has been 113.10% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -10.50%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -8.70%. This publicly-traded company’s shares outstanding now amounts to $135.33 million, simultaneously with a float of $133.34 million. The organization now has a market capitalization sitting at $1.24 billion. At the time of writing, stock’s 50-day Moving Average stood at $6.37, while the 200-day Moving Average is $7.01.

It is quite necessary to find out the efficiency of the corporate organization, which has 186 number of employees on its payroll. For the Profitability, stocks gross margin was +88.19, operating margin was -5154.28 and Pretax Margin of -5204.08.

TG Therapeutics Inc. (TGTX) Ownership Facts and Figures

Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. TG Therapeutics Inc.’s current insider ownership accounts for 1.10%, in contrast to 69.80% institutional ownership. According to the most recent insider trade that took place on Jan 05, this organization’s CEO and President sold 30,671 shares at the rate of 18.31, making the entire transaction reach 561,586 in total value, affecting insider ownership by 10,988,021. Preceding that transaction, on Jan 05, Company’s CFO, Secretary and Treasurer sold 9,653 for 18.31, making the whole transaction’s value amount to 176,746. This particular insider is now the holder of 568,483 in total.

TG Therapeutics Inc. (TGTX) Earnings and Revenue Records

As on 6/29/2022, Multinational firm has announced its last quarter scores, in which it reported -$0.3 earnings per share (EPS) for the period topping the consensus outlook (set at -$0.51) by $0.21. This company achieved a net margin of -5204.08 while generating a return on equity of -92.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.39 per share during the current fiscal year.

TG Therapeutics Inc.’s EPS decrease for this current 12-month fiscal period is -8.70% and is forecasted to reach -1.14 in the upcoming year.

TG Therapeutics Inc. (NASDAQ: TGTX) Trading Performance Indicators

Let’s observe the current performance indicators for TG Therapeutics Inc. (TGTX). It’s Quick Ratio in the last reported quarter now stands at 5.00. The Stock has managed to achieve an average true range (ATR) of 0.73. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 247.91.

In the same vein, TGTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.78, a figure that is expected to reach -0.26 in the next quarter, and analysts are predicting that it will be -1.14 at the market close of one year from today.

Technical Analysis of TG Therapeutics Inc. (TGTX)

Going through the that latest performance of [TG Therapeutics Inc., TGTX]. Its last 5-days volume of 2.22 million was inferior to the volume of 2.81 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 52.44% While, its Average True Range was 0.76.


Please enter your comment!
Please enter your name here